These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31422591)

  • 1. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
    Huang XM; Zhang Y; Xu L; Wang M; Wang W
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
    Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
    Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cells critical for outcome in high grade serous ovarian carcinoma.
    Vledder A; Paijens ST; Loiero D; Maagdenberg A; Duiker EW; Bart J; Hendriks AM; Jalving M; Werner N; van Rooij N; Plat A; Wisman GBA; Yigit R; Roelofsen T; Kruse AJ; de Lange NM; Koelzer VH; de Bruyn M; Nijman HW
    Int J Cancer; 2024 Dec; 155(12):2265-2276. PubMed ID: 39175107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Tomsová M; Melichar B; Sedláková I; Steiner I
    Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor infiltrating lymphocytes profile and response in neoadjuvant chemotherapy-treated triple-negative breast carcinoma patients.
    Ray D; Gupta SD; De A; Jain P; Bhattacharya NK; Biswas PK
    J Cancer Res Ther; 2022; 18(6):1782-1788. PubMed ID: 36412444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
    Jäntti T; Luhtala S; Mäenpää J; Staff S
    Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
    West NR; Milne K; Truong PT; Macpherson N; Nelson BH; Watson PH
    Breast Cancer Res; 2011; 13(6):R126. PubMed ID: 22151962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
    Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
    Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.